Join
Live feed
·
PRReleasevia Quantisnow
Bicara Therapeutics Inc. logo

Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC

ByQuantisnow·Wall Street's wire, on your screen.
BCAX· Bicara Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BCAX (Bicara Therapeutics Inc.) and more on Quantisnow.